Clinical trial NCT06492122: Study With [225Ac]Ac-FL-020 in mCRPC Participants
Official title: A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of [225Ac]Ac-FL-020 in Participants With mCRPC.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Metastatic Castration-resistant Prostate Cancer
Keywords: Safety
RP2D
Pharmacokinetics
Dosimetry
Preliminary efficacy
Dose escalation
Dose expansion
PSMA
Lead sponsor: Full-Life Technologies GmbH
Sponsor class: INDUSTRY
First posted: 2024-07-09
Enrollment: 35
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Dose escalation and dose expansion
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety, therapeutic effect, and pharmacokinetics of \[225Ac\]Ac-FL-020 in participants with metastatic castration-resistant prostate cancer (mCRPC).

Detailed description: The aim of this Phase 1, First-in-Human, Open-label Trial is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of \[225Ac\]Ac-FL-020 as a single agent in participants with metastatic Castration-Resistant Prostate Cancer (mCRPC). \[111In\]In-FL-020 serves as a surrogate for 225Ac-FL-020 for dosimetry purposes. The trial is divided into two parts: dose escalation in Part 1 and cohort expansion in Part 2.

Eligibility criteria: Inclusion Criteria:

1. Histologically or cytologically confirmed metastatic CRPC.
2. Age ≥ 18 years.
3. Signed informed consent, and able and willing to comply with protocol requirements prior to any study procedures.
4. All patients are required to have one or more positive lesions detected by PSMA-PET/CT scan
5. Documented progression of the disease based on the Investigator judgement
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
7. Have a castrate serum testosterone \< 50 ng/dL or \<1.7 nmol/L. Patients must continue primary androgen deprivation with an LHRH analogue (agonist/antagonist) if they have not undergone bilateral orchiectomy.
8. Have previously been treated with at least one of the following:

   1. Androgen receptor signaling inhibitor (such as enzalutamide).
   2. CYP 17 inhibitor (such as abiraterone acetate).
9. Patients must have been previously treated with at least 1, but no more than 2 previous taxane regimens.
10. Adequate organ function as defined by:

    1. Absolute neutrophil count (ANC) ≥2 x 10\^9/L (2000/µL),
    2. Hemoglobin ≥10.0 g/dL,
    3. Platelets ≥90 x 10\^9/L (90 000/µL),
    4. Serum albumin \>3g/dL
    5. Aspartate aminotransferase (AST) ≤2.5 x ULN; alanine aminotransferase (ALT) ≤2.5 x ULN (AST, ALT ≤5 x ULN if liver metastases are present),
    6. ALP ≤2.5 x ULN (ALP ≤5.0 x ULN, if liver or bone metastases are present),
    7. Serum total bilirubin ≤1.5 x ULN (≤5 x ULN if liver metastases present)
    8. Creatinine clearance ≥60 mL/min calculated using a standard Cockcroft and Gault formula.
    9. Q wave to T wave (QT) interval corrected for heart rate (QTc) \<470 ms

Exclusion Criteria:

1. Patients with known brain metastases.
2. Grade 3 Cystitis infective and non-infective.
3. Severe acute or chronic medical or psychiatric conditions or laboratory abnormality that may increase the risk associated with the study participation or the study treatment administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for enrollment in this study.
4. Previous treatment with Actinium-225, Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, or hemi-body irradiation or any other radionuclide therapy except \[177Lu\]Lu-PSMA-617 or Radium-223.
5. Radium-223 within 6 months prior to the first study treatment administration.
6. \[177Lu\]-Lu-PSMA-617 within 6 weeks prior to first study treatment administration. Adverse events related to \[177Lu\]Lu-PSMA-617 are required to be either resolved or of grade 1 prior to the first study treatment administration.
7. Any systemic anti-cancer therapy (e.g., chemotherapy, immunotherapy or biological therapy \[including monoclonal antibodies\]) within 6 weeks prior to the first study treatment administration. Patients on a stable bisphosphonate or denosumab regimen for 30 days prior to first study treatment administration are eligible.
8. Any investigational agents within 6 weeks prior to the first study treatment administration.
9. Radiotherapy: external beam radiotherapy that encompasses \>30% of bone marrow completed less than 6 weeks or focal radiation completed less than 2 weeks, prior to the first study treatment administration.
10. Major surgery (not including placement of vascular access device or tumor biopsies) within 6 weeks prior to first dose of the study treatment, or no recovery from side effects of such intervention.
11. Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression.
12. Known hypersensitivity to the components of the study therapy or its analogs.
13. Enrollment in another interventional clinical study.
14. Known history of myelodysplastic syndrome.

Primary outcomes:
measure: Dose escalation: Incidence of Dose-Limiting Toxicities (DLTs).
timeFrame: 28 days after the first injection of [225Ac]Ac-FL-020
measure: Dose escalation and dose expansion: Type, frequency and severity of adverse events (AEs) and serious adverse events (SAEs) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
timeFrame: From ICF signature and up to 42 days after the last dose of study treatment and then during the long-term follow-up period
Secondary outcomes:
measure: Dose escalation and dose expansion: Absorbed doses
timeFrame: During one week following the injection of [111In]In-FL-020
measure: Peak Plasma Concentration (Cmax)
timeFrame: During one week following the first injection of [225Ac]Ac-FL-020
measure: Area Under the Plasma concentration versus time curve
timeFrame: During one week following the first injection of [225Ac]Ac-FL-020
measure: Overall response rate
timeFrame: 2 years
measure: Disease Control Rate
timeFrame: 2 years
measure: Best Overall response
timeFrame: 2 years
measure: Progression Free Survival
timeFrame: 2 years
measure: Overall Survival
timeFrame: 2 years
Other outcomes:
Locations:
city: Duarte
country: United States
facility: City of Hope Medical Center
state: California
city: Stanford
country: United States
facility: University of Stanford
state: California
city: Brisbane
country: Australia
facility: Princess Alexandra Hospital
city: Murdoch
country: Australia
facility: Genesiscare Murdoch
Study officials:
affiliation: Full-Life Technologies GmbH
name: Full-Life Technologies GmbH
role: STUDY_DIRECTOR
References: